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This is an official
CDC HEALTH ADVISORY
CDC Recommends against the Use of Amantadine and Rimantadine for the 
Treatment or Prophylaxis of Influenza in the United States during the 2005­
06 Influenza Season
Recent evidence indicates that a high proportion o f currently circulating Influenza A viruses in this country are 
resistant to these medications
While the primary strategy for preventing complications of influenza infections is annual vaccination, antiviral 
medications with activity against influenza viruses can be effective for the prophylaxis and treatment of influenza. 
Two classes of antivirals are currently available—the M2 ion channel inhibitors (i.e., the two adamantanes 
amantadine and rimantadine) and the neuraminidase inhibitors (i.e., oseltamivir and zanamivir). The 
neuraminidase inhibitors are effective for the treatment and prophylaxis of influenza A and B, while the 
adamantanes are only active against influenza A viruses. This alert provides new information about the resistance 
of influenza viruses currently circulating in the United States to the adamantanes, and it makes an interim 
recommendation that these drugs not be used during the 2005-06  influenza season. Amantadine is also used to 
treat the symptoms of Parkinson's disease, and should continue to be used for this indication.
Viral resistance to adamantanes can emerge rapidly during treatment because a single point mutation at amino 
acid positions 26, 27, 30, 31, or 34 of the M2 protein can confer cross-resistance to both amantadine and 
rimantadine. The transmissibility of adamantane-resistant viruses is not impaired by any of these amino acid 
changes. A recent report on the global prevalence of adamantane-resistant influenza viruses showed a significant 
increase (from 1.9% to 12.3%) in drug resistance over the past 3 years. In the United States, the frequency of 
drug resistance increased from 1.9% in 2004 to 14.5% during the first 6 months of the 2004-05  influenza season.
For the 2005-06  season, 120 influenza A (H3N2) viruses isolated from patients in 23 states have been tested at 
CDC through January 12, 2006; 109 of the isolates (91%) contain an amino acid change at position 31 of the M2 
protein, which confers resistance to amantadine and rimantadine. Three influenza A(H1N1) viruses have been 
tested and demonstrated susceptibility to these drugs. All influenza viruses from the United States that have been 
screened for antiviral resistance at CDC have demonstrated susceptibility to the neuraminidase inhibitors.
On the basis of available antiviral testing results, CDC is providing an interim recommendation that neither 
amantadine nor rimantadine be used for the treatment or prophylaxis of influenza A in the United States for the 
remainder of the 2005-06  influenza season. During this period, oseltamivir or zanamivir should be selected if an 
antiviral medication is used for the treatment and prophylaxis of influenza. Testing of influenza isolates for 
resistance to antivirals will continue throughout the 2005- 06 influenza season, and recommendations will be 
updated as needed. Annual influenza vaccination remains the primary means of preventing morbidity and 
mortality associated with influenza.
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Additional information about the prevention and control of influenza is available at http://www.cdc.gov/flu/. Specific 
information regarding the use of the neuraminidase inhibitors is available at
http://www.cdc.gov/flu/protect/antiviral/index.htm. These websites will be updated as new information becomes 
available.
The Centers fo r Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and in juries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships w ith local, national and international
organizations.
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